Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Petit

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Transplantation Proceedings|August 1, 1997
French multicenter study of Neoral conversion in heart transplant patientsR Dorent, B Albat, V Baladier, et al.
Breast Cancer Research : BCR|December 3, 2025
<sup>18</sup>F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French studyM Chanchou, M A Mouret-Reynier, I Molnar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Molecular Psychiatry|June 21, 2007
Evidence for the association of the S100beta gene with low cognitive performance and dementia in the elderlyJ-C Lambert, S Ferreira, J Gussekloo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2016
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyO Trédan, P Follana, I Moullet, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 21, 2014
Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literatureS Ingen-Housz-Oro, N Franck, N Beneton, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Transplantation Proceedings|August 1, 1997
French multicenter study of Neoral conversion in heart transplant patientsR Dorent, B Albat, V Baladier, et al.
Breast Cancer Research : BCR|December 3, 2025
<sup>18</sup>F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French studyM Chanchou, M A Mouret-Reynier, I Molnar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2014
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trialH Bonnefoi, S Litière, M Piccart, et al.
Molecular Psychiatry|June 21, 2007
Evidence for the association of the S100beta gene with low cognitive performance and dementia in the elderlyJ-C Lambert, S Ferreira, J Gussekloo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 studyH Bonnefoi, W Jacot, M Saghatchian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2016
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyO Trédan, P Follana, I Moullet, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 21, 2014
Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or MALT lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literatureS Ingen-Housz-Oro, N Franck, N Beneton, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
Pageof 16